Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Neoplasm of Uncertain Histogenesis — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category
Neoplasm of Uncertain Histogenesis

Cancer

Neoplasm of Uncertain Histogenesis

CI-CAN-00000034Explore in graph →

Non-malignant20,280 active trials259 approved drugs3,813 evidence items

NCIt: C6974
OncoTree: MBT
UMLS CUI: C1334936

Overview
Statistics
Survival
Genomics465
Variants & evidence3813
Drugs427
Trials91351
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (4,399)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 3,851–3,875 of 4,399 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE study.
· PLoS One · 2013 · PMID 24236021 · validated civic_curation pubmed
LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin.
· Cancer Res · 2012 · PMID 22896685 · validated civic_curation pubmed
Mutant HRAS as novel target for MEK and mTOR inhibitors.
· Oncotarget · 2015 · PMID 26544513 · validated civic_curation pubmed
Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma.
· Cancer Biol Ther · 2015 · PMID 26046389 · validated civic_curation pubmed
BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.
· Clin Cancer Res · 2013 · PMID 24345920 · validated civic_curation pubmed
New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.
· Nat Chem Biol · 2015 · PMID 26436839 · validated civic_curation pubmed
MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor.
· Lung Cancer · 2015 · PMID 26547802 · validated civic_curation pubmed

Showing 3,851–3,875 of 4,399 publications

← Previous
1
…
154
155
156
…
176
Next →

Oncogenic RIT1 mutations in lung adenocarcinoma.

· Oncogene · 2014 · PMID 24469055 · validated civic_curation pubmed

Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma.

· Sci Transl Med · 2015 · PMID 26537256 · validated civic_curation pubmed

Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules.

· Cancer Cell · 2015 · PMID 26096845 · validated civic_curation pubmed

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.Retracted

· PLoS One · 2008 · PMID 18725974 · validated civic_curation pubmed

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

· Cancer Discov · 2013 · PMID 24065731 · validated civic_curation pubmed

Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.

· Int J Cancer · 2015 · PMID 25242168 · validated civic_curation pubmed

An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells.

· Cancer Cell · 2010 · PMID 20227043 · validated civic_curation pubmed

Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer.

· Sci Transl Med · 2013 · PMID 23390248 · validated civic_curation pubmed

FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers.

· Clin Cancer Res · 2015 · PMID 26015511 · validated civic_curation pubmed

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.

· Br J Cancer · 2011 · PMID 21119661 · validated civic_curation pubmed

Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer.

· PLoS One · 2015 · PMID 26267899 · validated civic_curation pubmed

KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine.

· Cancer Res · 2015 · PMID 25968887 · validated civic_curation pubmed

CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients.

· Clin Cancer Res · 2015 · PMID 25762343 · validated civic_curation pubmed

Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.

· J Oral Pathol Med · 2016 · PMID 25677871 · validated civic_curation pubmed

Caspase-8 expression is predictive of tumour response to death receptor 5 agonist antibody in Ewing's sarcoma.

· Br J Cancer · 2015 · PMID 26291055 · validated civic_curation pubmed

TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun.

· Oncotarget · 2016 · PMID 26745678 · validated civic_curation pubmed

Activation of AR sensitizes breast carcinomas to NVP-BEZ235's therapeutic effect mediated by PTEN and KLLN upregulation.

· Mol Cancer Ther · 2014 · PMID 24356815 · validated civic_curation pubmed

Mislocalization of p27 to the cytoplasm of breast cancer cells confers resistance to anti-HER2 targeted therapy.

· Oncotarget · 2014 · PMID 25587029 · validated civic_curation pubmed